Seiko Diane Yamada

Research Summary
Dr. Diane Yamada specializes in the diagnosis and treatment of gynecologic cancers. She is the Section Chief for Gynecologic Oncology at the University of Chicago. Her areas of interest include: Surgery for gynecologic malignancies including ovarian, uterine and cervical cancers, as well as minimally invasive surgery Prophylactic surgery for women at high risk for the development of hereditary ovarian and endometrial cancers Management of high grade uterine cancers Intraperitoneal chemotherapy Novel clinical trials Her research focuses on new treatments and drug development for ovarian and endometrial cancer, the regulation and radiologic imaging of ovarian cancer metastasis and the unique biology of aggressive uterine cancers. She conducts clinical trials targeting ovarian cancer as well as endometrial cancer. Dr. Yamada is an editorial reviewer for a number of academic medical journals, including the American Journal of Obstetrics and Gynecology, Gynecologic Oncology, and Cancer. She is also the author or co-author of numerous peer-reviewed publications, book chapters and reviews concerning gynecologic cancers. She holds national leadership positions on the gynecologic oncology board of the American Board of Obstetrics and Gynecology and she is President-Elect II for the Society of Gynecologic Oncology.
Keywords
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Clinical Trials, Randomized, Surgery
Education
  • University of California Los Angeles, MD
  • Harbor-UCLA Medical Center, Internship
  • Harbor-UCLA Medical Center, Residency
  • University of California, Irvine, Fellowship
Awards & Honors
  • 2014 - 2020 Division Board, Gynecologic Oncology American Board of Obstetrics and Gynecology
  • 2021 - 2022 President Society of Gynecologic Oncology
Publications
  1. Kondo T, Tasaka T, Shimizu R, Hayashi K, Yamada S, Fukuda H, Hirose T, Takeuchi A, Sano F, Tokunaga H, Matsuhashi Y, Wada H. Jumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature. Mol Clin Oncol. 2020 Apr; 12(4):365-373. View in: PubMed

  2. Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 07; 154(1):177-182. View in: PubMed

  3. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728. View in: PubMed

  4. Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16. View in: PubMed

  5. Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9. View in: PubMed

  6. Cowan M, Suntum T, Olivas AD, Perpich M, Applebaum MA, Lastra RR, Yamada SD. Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome. Gynecol Oncol Rep. 2018 Aug; 25:94-97. View in: PubMed

  7. Chapel DB, Yamada SD, Cowan M, Lastra RR. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018 06; 149(3):570-574. View in: PubMed

  8. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301. View in: PubMed

  9. Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME. Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. Int J Gynecol Cancer. 2017 10; 27(8):1774-1782. View in: PubMed

  10. Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266. View in: PubMed

  11. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351. View in: PubMed

  12. Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y. Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 11; 26(9):1642-1649. View in: PubMed

  13. Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175. View in: PubMed

  14. He C, Poon C, Chan C, Yamada SD, Lin W. Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. J Am Chem Soc. 2016 05 11; 138(18):6010-9. View in: PubMed

  15. He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W. Nanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May; 2(5):366-7. View in: PubMed

  16. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9. View in: PubMed

  17. Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr; 137(1):119-24. View in: PubMed

  18. West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014 Sep; 1(2):151-154. View in: PubMed

  19. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28. View in: PubMed

  20. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83. View in: PubMed

  21. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521. View in: PubMed

  22. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014 Feb 01; 120(3):344-51. View in: PubMed

  23. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7. View in: PubMed

  24. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. View in: PubMed

  25. Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10. View in: PubMed

  26. Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20. View in: PubMed

  27. Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013 Jan 15; 119(2):325-31. View in: PubMed

  28. Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW. Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis. 2012 Jun; 29(5):397-408. View in: PubMed

  29. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012 Feb; 13(2):154-62. View in: PubMed

  30. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7. View in: PubMed

  31. Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8. View in: PubMed

  32. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503. View in: PubMed

  33. Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6. View in: PubMed

  34. Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST. Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 2011 Jun 15; 117(12):2643-51. View in: PubMed

  35. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51. View in: PubMed

  36. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8. View in: PubMed

  37. Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23. View in: PubMed

  38. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71. View in: PubMed

  39. Suzuki H, Yamada S, Toyama Y, Takeda S. The C-terminal domain is sufficient for host-binding activity of the Mu phage tail-spike protein. Biochim Biophys Acta. 2010 Sep; 1804(9):1738-42. View in: PubMed

  40. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96. View in: PubMed

  41. Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51. View in: PubMed

  42. Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204. View in: PubMed

  43. Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CW. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 2008 Dec 08; 272(1):12-22. View in: PubMed

  44. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9. View in: PubMed

  45. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39. View in: PubMed

  46. Lotan T, Hickson J, Souris J, Huo D, Taylor J, Li T, Otto K, Yamada SD, Macleod K, Rinker-Schaeffer CW. c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation. Cancer Res. 2008 Apr 01; 68(7):2166-75. View in: PubMed

  47. Lotan TL, Tefs K, Schuster V, Miller J, Manaligod J, Filstead A, Yamada SD, Krausz T. Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Hum Pathol. 2007 Oct; 38(10):1569-75. View in: PubMed

  48. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72. View in: PubMed

  49. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9. View in: PubMed

  50. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8. View in: PubMed

  51. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65. View in: PubMed

  52. Ruddat M. Gibberellin-like Substances From Vegetative Tissue of a Conifer, Arizona Cypress. Plant Physiol. 1968 Dec; 43(12):2049-53. View in: PubMed

  53. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006 Feb 15; 66(4):2264-70. View in: PubMed

  54. Kimata Y, Ishiwata-Kimata Y, Yamada S, Kohno K. Yeast unfolded protein response pathway regulates expression of genes for anti-oxidative stress and for cell surface proteins. Genes Cells. 2006 Jan; 11(1):59-69. View in: PubMed

  55. Dewdney S, Sokoloff M, Yamada SD. Conservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma. Gynecol Oncol. 2006 Mar; 100(3):608-11. View in: PubMed

  56. Birch LE, Ruddat M. Siderophore accumulation and phytopathogenicity in Microbotryum violaceum. Fungal Genet Biol. 2005 Jul; 42(7):579-89. View in: PubMed

  57. Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small W, Mundt AJ. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1078-86. View in: PubMed

  58. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5546-53. View in: PubMed

  59. Citron JR, Sutton H, Yamada SD, Mehta N, Mundt AJ. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1432-8. View in: PubMed

  60. Rana S, Warren BK, Yamada SD. Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy. Obstet Gynecol. 2004 May; 103(5 Pt 2):1120-3. View in: PubMed

  61. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004 Mar; 92(3):801-5. View in: PubMed

  62. Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9. View in: PubMed

  63. Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):516-21. View in: PubMed

  64. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6. View in: PubMed

  65. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1388-96. View in: PubMed

  66. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23. View in: PubMed

  67. Tsuchida R, Miyauchi J, Shen L, Takagi M, Tsunematsu Y, Saeki M, Honna T, Yamada S, Teraoka H, Kato JY, Mizutani S. Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res. 2002 Sep; 93(9):1000-6. View in: PubMed

  68. Garber ED, Ruddat M. Transmission genetics of Microbotryum violaceum (Ustilago violacea): a case history. Adv Appl Microbiol. 2002; 51:107-27. View in: PubMed

  69. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7. View in: PubMed

  70. Phelan C, Montag AG, Rotmensch J, Waggoner SE, Yamada SD, Mundt AJ. Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment. Gynecol Oncol. 2001 Dec; 83(3):513-7. View in: PubMed

  71. Adams SF, Yamada SD, Montag A, Rotmensch JR. An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium. Gynecol Oncol. 2001 Nov; 83(2):418-21. View in: PubMed

  72. Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, Rotmensch J. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63. View in: PubMed

  73. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1154-60. View in: PubMed

  74. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1145-53. View in: PubMed

  75. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) Nature. 1996 Dec 05; 384(6608):455-8. View in: PubMed